AGC Biologics has announced the appointment of Alberto Santagostino as its new Chief Executive Officer and President, effective November 1st, signaling a strategic shift towards offering more reliable and uncomplicated services for biopharmaceutical developers. Santagostino, with his extensive background in the biopharmaceutical industry, including his recent role as the Head of Cell and Gene Technology at Lonza, is poised to lead AGC Biologics into its next growth phase. His experience in transforming CGT manufacturing into industrial-scale operations and his strategic insights from McKinsey & Co. are expected to drive the company's new direction.
The appointment reflects AGC Biologics' ambition to become a 'friendly CDMO expert,' focusing on collaboration, reliability, and stability to navigate industry challenges such as geopolitical risks and intellectual property concerns. Murano Tadashi, President of AGC Life Science Company, has expressed confidence in Santagostino's leadership to enhance the company's standing in the industry. Santagostino's vision for AGC Biologics centers on placing customers at the core of the company's actions and leveraging technical talent to provide expert services, encapsulated by the tagline '#YourfriendlyCDMOexpert.'
AGC Biologics, with its 30-year history in biopharma CDMO services, operates a global network of cGMP-compliant facilities and has contributed to the launch of 25 commercial products. The company's repositioning under Santagostino's leadership is timely, as the biopharmaceutical industry grapples with increasing complexity in drug development and manufacturing. This strategic shift could offer drug developers a more collaborative and less complicated partnership option, addressing a critical need in the industry. For more information on AGC Biologics and its services, visit https://www.agcbio.com.
